Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Futile treatment regime for primary biliary cirrhosis

Methotrexate, when added to ursodeoxycholic acid for a median period of 7 years, has no effect on the course of primary biliary cirrhosis, reports the latest issue of Hepatology.

News image

fiogf49gjkf04

Dr Burton Combes and colleagues compared the effects of combination therapy on the course of primary biliary cirrhosis.

The research team assessed the effects of methotrexate plus ursodeoxycholic acid to ursodeoxycholic acid alone.

The team conducted a placebo-controlled, randomized, multicenter trial.

The researchers stratified 265 AMA positive patients according to Ludwig's histological staging.

The patients presented without ascites, variceal bleeding, or encephalopathy.

The team reported that the patients had a serum bilirubin less than 3 mg/dL, serum albumin 3 g/dL or greater.

The patients had also taken ursodeoxycholic acid 15 mg/kg daily for at least 6 months.

Occurrence of treatment failures with ursodeoxycholic acid plus methotrexate vs single treatment did not differ
Hepatology

The researchers randomized the patients to methotrexate 15 mg/m2 body surface area once a week while continuing on ursodeoxycholic acid.

The median time from randomization to closure of the study was 7 years.

Treatment failure was defined as death without liver transplantation, transplantation, variceal bleeding, and development of ascites.

The researchers also included encephalopathy, or varices, a doubling of serum bilirubin to 2.5 mg/dL or greater as definitions of treatment failure.

A fall in serum albumin to 2.5 g/dL or less, and histological progression by at least 2 stages or to cirrhosis was included in the definition of treatment failure.

The team continued patients on treatment despite failure of treatment, unless transplantation ensued.

If drug toxicity necessitated withdrawal, or the patient developed a cancer, treatment was discontinued.

The researchers found no significant differences in these parameters.

No differences were observed in the time of development of treatment failures with ursodeoxycholic acid plus methotrexate, or ursodeoxycholic acid plus placebo.

The research team conducted the trial with a stopping rule.

The team reported that the trial was stopped early by the National Institutes of Health at the advice of the Data Safety Monitoring Board for reasons of futility.

Dr Combes' team concludes, “Methotrexate when added to ursodeoxycholic acid for a median period of 7 years had no effect on the course of primary biliary cirrhosis treated with ursodeoxycholic acid alone.”

Hepatol 2005: 42(5): 1184-93
01 November 2005

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 21 February 2018 
Management of hemorrhoids in the USA
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us